Results have been quite promising on reducing the functional and structural lung abnormalities commonly associated with PPHN, not only when used in combination to therapies targeting interacting pathways, such as NO/GMP or ET-1, but also when used independently (56–58, 98). The gene discussed is EDN1; the disease is persistent fetal circulation syndrome.